Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 63-68

  Rauh Hain, J Alejandro ^a   Nitschmann, Caroline C ^a,b   Worley Jr , Micheal J ^b   Bradford, Leslie S ^a   Berkowitz, Ross S ^b   Schorge, John O ^a   Campos, Susana M ^b   Del Carmen, Marcela G ^a   Horowitz, Neil S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer; Platinum resistance

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INIPARIB; PACLITAXEL; PRALATREXATE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 84875424539     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.01.009     Document Type: Article

References (23)

1. R. Sankaranarayanan, and J. Ferlay Worldwide burden of gynaecological cancer: the size of the problem Best Pract Res Clin Obstet Gynaecol 20 2006 207 225
2. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 60 5 2010 277 300
3. S.A. Cannistra Cancer of the ovary N Engl J Med 351 24 2004 2519 2529
4. R.J. Morgan Jr., R.D. Alvarez, D.K. Armstrong, L.M. Chen, L. Copeland, and J. Fowler Ovarian cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 9 2006 912 939
5. J.A. Rauh-Hain, N. Rodriguez, W.B. Growdon, and A.K. Goodman Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer Ann Surg Oncol 19 3 2012 959 965
6. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 2010 943 953
7. A.L. Covens A critique of surgical cytoreduction in advanced ovarian cancer Gynecol Oncol 78 3 Pt 1 2000 269 274
8. E.L. Eisenhauer, R.E. Bristow, and D.S. Chi Neoadjuvant chemotherapy for ovarian cancer: pro versus con Wom Oncol Rev 6 1-2 2006 27 35
9. L. Norton, and R. Simon Tumor size sensitivity to therapy and design of treatment schedules Cancer Treat Rep 61 1977 1307 1317
10. J.H. Goldie, and J.A. Coldman A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 63 1979 1727 1733
11. WHO handbook for reporting results of cancer treatments 1979 World Health Organization Geneva (WHO offset publication no. 48)
12. M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
13. M. Markman Recurrence within 6 months of platinum therapy: an adequate definition of "platinum-refractory" ovarian cancer? Gynecol Oncol 69 1998 91 92
14. A.N. Fader, and P.G. Rose Role of surgery in ovarian carcinoma J Clin Oncol 25 2007 2873 2883
15. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2 2007 480 490
16. R.E. Bristow, R.S. Tomacruz, D.K. Amstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259
17. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 1 2000 26 35
18. M. Markman Pharmaceutical management of ovarian cancer: current status Drugs 68 6 2008 771 789
19. A. Richardson, and S.B. Kaye Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Updat 8 2005 311 321
20. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 7 2007 573 584
21. K. Matsuo, M.L. Eno, D.D. Im, and N.B. Rosenshein Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas Arch Gynecol Obstet 281 2010 325 328
22. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 3 2006 1070 1076
23. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 8 2009 2315 2320